These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1000 related articles for article (PubMed ID: 26883357)

  • 61. Preclinical models of pancreatic ductal adenocarcinoma.
    Krempley BD; Yu KH
    Chin Clin Oncol; 2017 Jun; 6(3):25. PubMed ID: 28705002
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Beyond the Genomic Mutation: Rethinking the Molecular Biomarkers of K-RAS Dependency in Pancreatic Cancers.
    Mottini C; Cardone L
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708716
    [TBL] [Abstract][Full Text] [Related]  

  • 63. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
    Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Alteration of tumor-associated macrophage subtypes mediated by KRT6A in pancreatic ductal adenocarcinoma.
    Zhang J; Sun H; Liu S; Huang W; Gu J; Zhao Z; Qin H; Luo L; Yang J; Fang Y; Ge J; Ni B; Wang H
    Aging (Albany NY); 2020 Nov; 12(22):23217-23232. PubMed ID: 33221741
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer.
    Weng CC; Hsieh MJ; Wu CC; Lin YC; Shan YS; Hung WC; Chen LT; Cheng KH
    Mol Cancer; 2019 May; 18(1):96. PubMed ID: 31109321
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer.
    Nagathihalli NS; Castellanos JA; Lamichhane P; Messaggio F; Shi C; Dai X; Rai P; Chen X; VanSaun MN; Merchant NB
    Cancer Res; 2018 Nov; 78(21):6235-6246. PubMed ID: 30154150
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mir34a constrains pancreatic carcinogenesis.
    Hidalgo-Sastre A; Lubeseder-Martellato C; Engleitner T; Steiger K; Zhong S; Desztics J; Öllinger R; Rad R; Schmid RM; Hermeking H; Siveke JT; von Figura G
    Sci Rep; 2020 Jun; 10(1):9654. PubMed ID: 32541781
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Precision Medicine and Pancreatic Cancer.
    George B
    Surg Oncol Clin N Am; 2021 Oct; 30(4):693-708. PubMed ID: 34511190
    [TBL] [Abstract][Full Text] [Related]  

  • 71. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis.
    Tanaka M; Suzuki HI; Shibahara J; Kunita A; Isagawa T; Yoshimi A; Kurokawa M; Miyazono K; Aburatani H; Ishikawa S; Fukayama M
    Oncogene; 2014 May; 33(19):2454-63. PubMed ID: 23752186
    [TBL] [Abstract][Full Text] [Related]  

  • 72. New therapeutic targets in pancreatic cancer.
    Lai E; Puzzoni M; Ziranu P; Pretta A; Impera V; Mariani S; Liscia N; Soro P; Musio F; Persano M; Donisi C; Tolu S; Balconi F; Pireddu A; Demurtas L; Pusceddu V; Camera S; Sclafani F; Scartozzi M
    Cancer Treat Rev; 2019 Dec; 81():101926. PubMed ID: 31739115
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment.
    Wood LD; Canto MI; Jaffee EM; Simeone DM
    Gastroenterology; 2022 Aug; 163(2):386-402.e1. PubMed ID: 35398344
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Regulation and function of autophagy in pancreatic cancer.
    Li J; Chen X; Kang R; Zeh H; Klionsky DJ; Tang D
    Autophagy; 2021 Nov; 17(11):3275-3296. PubMed ID: 33161807
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Genetics and biology of pancreatic ductal adenocarcinoma.
    Hezel AF; Kimmelman AC; Stanger BZ; Bardeesy N; Depinho RA
    Genes Dev; 2006 May; 20(10):1218-49. PubMed ID: 16702400
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Advances in Systemic Therapy in Pancreatic Cancer.
    Yu KH
    Hematol Oncol Clin North Am; 2024 Jun; 38(3):617-627. PubMed ID: 38575456
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic.
    Fokas E; O'Neill E; Gordon-Weeks A; Mukherjee S; McKenna WG; Muschel RJ
    Biochim Biophys Acta; 2015 Jan; 1855(1):61-82. PubMed ID: 25489989
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The roles of intratumour heterogeneity in the biology and treatment of pancreatic ductal adenocarcinoma.
    Evan T; Wang VM; Behrens A
    Oncogene; 2022 Oct; 41(42):4686-4695. PubMed ID: 36088504
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Single-cell profiling to explore pancreatic cancer heterogeneity, plasticity and response to therapy.
    Bärthel S; Falcomatà C; Rad R; Theis FJ; Saur D
    Nat Cancer; 2023 Apr; 4(4):454-467. PubMed ID: 36959420
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pancreatic Cancer: Genetic Conditions and Epigenetic Alterations.
    Montalvo-Javé EE; Nuño-Lámbarri N; López-Sánchez GN; Ayala-Moreno EA; Gutierrez-Reyes G; Beane J; Pawlik TM
    J Gastrointest Surg; 2023 May; 27(5):1001-1010. PubMed ID: 36749558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 50.